News

On April 16, 2020, Wisconsin Secretary-designee of the Department of Health Services, Andrea Palm, issued Emergency Order #28 at the direction of Governor Tony Evers. This new Order extends Wisconsin’s “Safer at Home” Order until 8:00 a.m. on May 26, 2020, or until a superseding order is issued, and modifies the original order. The original Safer at Home Order issued on March 25, Emergency Order #12, remains in effect until April 24, 2020.

BioForward is actively engaged with community partners, elected officials, state agencies and industry partners to meet the challenges of combating the coronavirus and demonstrating that Wisconsin can help lead the nation through this healthcare crisis. PPE Focus Eight Madison-area community providers serving people with developmental disabilities and seniors received much-needed PPE as they battle the […]

Jocelyn Cao joined the BioForward Wisconsin team in July 2020 as the Communication and Events Coordinator Intern. Jocelyn is a junior at the University of Wisconsin-Madison, pursuing a Bachelor of Science in Biology and in Life Science Communications.  As the Communications and Events Coordinator Intern, Jocelyn will be assisting with general communications needs, social media, […]

In June 2018, University of Wisconsin-Madison student and Wisconsin native, Cate Wilkinson, joined the team at BioForward Wisconsin as our Communications, Marketing, and Events Intern.  She was going to school to earn her Bachelor of Science in Microbiology. She thought that joining BioForward, as a biohealth membership association, would afford her the opportunity to learn […]

Read the full press release from Catalent here. Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19. Under the terms […]

Read the full press release from Illumina here. Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. […]

Read the full story from WISBUSINESS here. Virologists at the Morgridge Institute for Research are investigating the biology of viruses and their diseases in order to develop powerful new methods to not only control COVID-19 but stem the next pandemic. According to the institute, COVID-19 illustrates how viral threats are growing more common, underscoring the […]

Read the full press release from Eurofins here. Eurofins Technologies announces the launch of a serology-based total antibody (IgG, IgA and IgM) detection ELISA assay for indirect diagnostic of past exposure to COVID-19. The development of the assay has been led by Eurofins Ingenasa, a Eurofins Technologies company involved in the development of diagnostic tests […]